← Back to patent-cliff list
TAVT-45
Tier C — Watch / tradeTAVT-45
Tavanta Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP17A1
Indications (approved)：Castration-resistant prostate cancer
Regional status
US
Phase III
2025-07-01
EU
Phase III
2025-07-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TAVT-45?
Approved indications include: Castration-resistant prostate cancer.
When does the TAVT-45 patent expire?
No public expiry year is available for TAVT-45 yet; this page updates once verified.
How do I get a quote for TAVT-45 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30